• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

business development

Graphic for The Top Line podcast featuring a pale blue background with a repeating pattern of blue-and-white capsules a
Podcast

The deal before the deal

Big Pharma dealmaking has picked up, but the biotech path to a signed agreement is still anything but simple.
Ayla Ellison , James Waldron Jun 26, 2026 9:20am
Pfizer

A 5-month sprint: Inside Pfizer's $10B deal with Innovent

Jun 21, 2026 10:41pm
Lilly

Lilly’s $2.3B Ajax drug works ‘right out of the gate’

Jun 13, 2026 11:15am
Astellas
Favicon Fierce Pharma

Inside Astellas CEO's plan to counter Xtandi's patent cliff

Jun 11, 2026 6:00pm
handshake deal shake hand arrows ok yes
Favicon Fierce Pharma

Novavax bets on ‘amplification strategy’ with Sanofi, Pfizer deals

Apr 6, 2026 8:37am
Darsow

With 200 JPM meetings, Novo BD head seeks out the next Metsera

Jan 27, 2026 5:25pm

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings